Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05903274 · ClinicalTrials.gov registry record · Phase 1
JSP191 (briquilimab) in Subjects with LR-MDS
A Phase 1 study, sponsored by Jasper Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05903274 is a Phase 1 study that was terminated before completion, run by Jasper Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05903274, a Phase 1 study, was terminated before completion, sponsored by Jasper Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
Interventions
- DRUG JSP191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2024-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05903274
The ClinicalTrials.gov registry entry for NCT05903274 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasper Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JSP191 is the first listed.
NCT05903274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05903274 about?
NCT05903274 is a clinical study titled "JSP191 (briquilimab) in Subjects with LR-MDS". A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
What is the current status of trial NCT05903274?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-06-19. Estimated completion is 2024-10-21.
What interventions are being tested in trial NCT05903274?
The interventions under investigation include: JSP191 (DRUG).
Who is sponsoring clinical trial NCT05903274?
This trial is sponsored by Jasper Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.